Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINT: Tecemotide in Rectal Cancer
NCT01507103Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2012
- Primary completion
- Jun 2014
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tecemotide in rectal cancer, sponsored by Merck KGaA. Started Feb 2012; status: completed.
02
Drugs
tecemotide
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01507103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01507103.